Neurogene
Suzanne R. Burstein is a seasoned professional in the field of preclinical development with a strong background in neuroscience and neurodegenerative diseases. Currently serving as Senior Director of Preclinical at Neurogene Inc. since December 2020, Suzanne has advanced through various roles, including Director and Associate Director of Preclinical Development. Prior experience includes positions as a Scientist and Associate Scientist at Prevail Therapeutics, as well as a Postdoctoral Research Fellow at The New York Stem Cell Foundation Research Institute. Suzanne's academic background includes a PhD from Joan & Sanford I. Weill Medical College of Cornell University, where research focused on mitochondrial dysfunction in neurodegenerative disease. Additional educational credentials include a Bachelor of Science in Biology from Lehigh University.
This person is not in any offices
Neurogene
Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring to patients therapies that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technology to develop treatments for diseases not well served by gene therapy.